Strong facts, held-back story: management reports concrete strengthening but deliberately keeps expectations below it
The model's full reasoning — Q4 2017 call → NOWe need to determine if management both reports concrete, already-occurring strength in the business AND visibly holds the story back from that strength. The transcript is about Intra-Cellular Therapies, a biotech company. The "business" here is drug development, not sales. Strength could be progress in clinical trials, positive data, regulatory milestones, etc. The question asks about "rising orders, volumes, customers, activity, wins, utilization, or output" but in a biotech context, it's about clinical progress, data, regulatory filings, etc. We need to see if management reports concrete, already-occurring strength: e.g., positive trial results, progress in development, strong safety profile, etc. And then whether they deliberately keep expectations modest, e.g., not raising guidance, cautioning against extrapolation, emphasizing risks, etc. Let's review the transcript. Management discusses achievements: lumateperone development, NDA submission planned, positive trials, safety data, etc. They mention "we are encouraged by our prospects" and "we believe about schizophrenia clinical development program provides strong evidence of the efficacy and favorable safety profile." They also mention "we intend to submit our NDA for lumateperone for the treatment of schizophrenia by mid-2018." They have a pre-NDA meeting. They also discuss other programs. But is there any concrete, already-occurring strength? Yes, they have positive clinical trial results, they have completed studies, they have data. They also have financial results: cash position, etc. But the question is about "real improvement in the recent period" such as rising orders, volumes, etc. In a biotech, it could be progress in trials, positive data, regulatory milestones. They report that they have completed the first part of an open-label safety switching study with positive results. They have initiated a Phase 1/2 trial for ITI-214. They have started activities for another study. They have raised capital. So there is progress. Now, do they hold the story back? Do they deliberately keep expectations modest? Look for statements where they caution against extrapolating, or emphasize risks, or decline to raise guidance. They give guidance for 2018 spending of $180-200 million. They don't give revenue guidance because they have no product. They talk about future plans.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| GL | Globe Life Inc. | Q1 2024 | 2024-04-23 | F |
| PBR | Petróleo Brasileiro S.A. - Petrobras | Q4 2023 | 2024-03-08 | D |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| EGP | EastGroup Properties, Inc. | Q4 2023 | 2024-02-08 | B |
| MET | MetLife, Inc. | Q4 2023 | 2024-02-01 | B+ |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| AEP | American Electric Power Company, Inc. | Q3 2023 | 2023-11-02 | C+ |
| PNNT | PennantPark Investment Corporation | Q3 2023 | 2023-08-10 | B+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| DAL | Delta Air Lines, Inc. | Q2 2023 | 2023-07-13 | A |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| THS | TreeHouse Foods, Inc. | Q1 2023 | 2023-05-08 | B+ |
| SBRA | Sabra Health Care REIT, Inc. | Q1 2023 | 2023-05-04 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| UAL | United Airlines Holdings, Inc. | Q4 2022 | 2023-01-18 | B |
| ICL | ICL Group Ltd | Q3 2022 | 2022-11-09 | B+ |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| CIVB | Civista Bancshares, Inc. | Q2 2022 | 2022-07-31 | B |
| LIN | Linde plc | Q2 2022 | 2022-07-28 | B+ |
| PRGS | Progress Software Corporation | Q2 2022 | 2022-06-28 | B+ |
| SQM | Sociedad Química y Minera de Chile S.A. | Q1 2022 | 2022-05-19 | C+ |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| FARM | Farmer Bros. Co. | Q3 2022 | 2022-05-07 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| VVV | Valvoline Inc. | Q1 2022 | 2022-02-09 | C+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| ALHC | Alignment Healthcare, Inc. | Q3 2021 | 2021-11-06 | B+ |
| WMB | The Williams Companies, Inc. | Q3 2021 | 2021-11-02 | B |
| SXC | SunCoke Energy, Inc. | Q3 2021 | 2021-11-01 | A |
| MD | Pediatrix Medical Group, Inc. | Q3 2021 | 2021-10-28 | B |
| CPRX | Catalyst Pharmaceuticals, Inc. | Q2 2021 | 2021-08-10 | C+ |
| AMC | AMC Entertainment Holdings, Inc. | Q2 2021 | 2021-08-09 | D |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| CRS | Carpenter Technology Corporation | Q4 2021 | 2021-08-01 | A |
| AX | Axos Financial, Inc. | Q4 2021 | 2021-07-29 | C+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| HPE | Hewlett Packard Enterprise Company | Q2 2018 | 2018-05-22 | B+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| FOSL | Fossil Group, Inc. | Q1 2018 | 2018-05-08 | C |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| PCRX | Pacira BioSciences, Inc. | Q4 2017 | 2018-02-28 | C |
| TSLX | Sixth Street Specialty Lending, Inc. | Q4 2017 | 2018-02-22 | C+ |
| LII | Lennox International Inc. | Q4 2017 | 2018-02-06 | B+ |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| RACE | Ferrari N.V. | Q3 2017 | 2017-11-02 | C+ |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| PII | Polaris Inc. | Q3 2017 | 2017-10-24 | C+ |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| ABM | ABM Industries Incorporated | Q2 2017 | 2017-06-08 | B |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| AAT | American Assets Trust, Inc. | Q4 2016 | 2017-02-15 | C+ |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
| BMO | Bank of Montreal | Q4 2016 | 2016-12-06 | B |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| WAT | Waters Corporation | Q3 2016 | 2016-10-25 | C |
| BOH | Bank of Hawaii Corporation | Q3 2016 | 2016-10-24 | A |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| TRV | The Travelers Companies, Inc. | Q2 2016 | 2016-07-21 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| INGR | Ingredion Incorporated | Q1 2016 | 2016-05-01 | B+ |
| SPR | Spirit AeroSystems Holdings, Inc. | Q1 2016 | 2016-04-29 | D |
| ACCO | ACCO Brands Corporation | Q1 2016 | 2016-04-27 | B+ |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| CAL | Caleres, Inc. | Q4 2015 | 2016-03-15 | C+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| JHX | James Hardie Industries plc | Q3 2016 | 2016-02-19 | B+ |
GTES · Q4 2021 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND visibly HOLD THE STORY BACK from that strength? YES Management reports concrete, already-occurring strength in the business—rising orders, record backlog, book-to-build above 1, strong January order rates, specific design wins, and demand exceeding supply—while deliberately holding the story back by framing 2022 expectations as measured, pragmatic, and cautious, noting ongoing challenges through Q1 and not fully embedding the current momentum into the guidance range. This posture appears in their own words as they describe the facts running ahead of the outlook they are willing to share. The restraint is not mere boilerplate but a visible choice to under-promise relative to the reported strength.
BCOV · Q1 2018 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND visibly HOLD THE STORY BACK from that strength? YES Management reports concrete strength in Q1 2018: revenue $41.2M exceeded high end of guidance, adjusted EBITDA positive $900k well above high end, recurring dollar retention 103% (multi-year high), strong bookings across businesses/geographies, notable wins including large auto company deal, Europe best 3+ years, completed commodity pricing reset, and digital marketing/enterprise activity showing productivity gains. They visibly hold the story back: full-year revenue guidance $165-168M (roughly flat vs. Q1 run-rate implying ~$164.8M), Q2 revenue guidance $41.
PII · Q3 2017 → YESThe question is: Does management BOTH report concrete, already-occurring strength AND hold the story back from that strength? YES The transcript shows clear evidence of both elements in management's posture. They report concrete, already-occurring strength in the recent period—Q3 sales up 25% (adjusted), North American retail up 13% with RZR and NDN ahead, September as Polaris' highest retail month ever, August among top three 2017 months, off-road vehicles and Polaris retail up versus 2015 (not an easy comp), dealer inventory down 7%, and strong international/PG&A growth—while explicitly raising 2017 guidance (sales 18-19%, ORV/Snow mid-single digits, EPS $4.